Archive · 2 Jun 2025
Supriya Lifescience Targets 20% Revenue Growth with Strong Margins
Supriya Lifescience, a Mumbai-based company, plans to grow its revenue by 20% each year.
In the latest quarter, they made more money than the previous year, with revenue up and profits up.
They expect to keep making good profits, even if the profit margin goes down a little.
A lot of their money comes from selling in countries that have strict rules.
They are also expecting more revenue from selling a vitamin ingredient to a European company over the next 10 years.
They are focusing on growing sales in Europe and Latin America.
The company's focus is on their current portfolio including anesthetics, ADHD, and cardiovascular products.
Supriya Lifescience aims for 20% annual revenue growth, maintaining robust EBITDA margins.
Q4FY25 revenue rose 16.4% to ₹184.1 crore, and profit after tax jumped 36.4% to ₹50.4 crore.
Margins are expected to stabilize between 33% and 35% in the coming quarters.
Approximately 50% of revenue comes from regulated markets, expecting to rise to 60% in the near term.
The company secured a 10-year API supply contract for a vitamin product with expected annual revenue of ₹60-70 crore.
- Who
- Supriya Lifescience
- What
- Supriya Lifescience is targeting 20% annual revenue growth.
- When
- Q4FY25, and the coming years
- Where
- Mumbai
- Why
- To achieve a 20% revenue growth while maintaining strong margins
- Revenue Growth Target
- 20% annually
- Q4FY25 Revenue
- ₹184.1 crore
- Q4FY25 Profit After Tax
- ₹50.4 crore
- Current Revenue from Regulated Markets
- 50%
- Expected Revenue from Regulated Markets
- 60% (near term)
- API Supply Contract
- 10-year exclusive contract
- Vitamin Product Revenue (Peak)
- ₹60-70 crore annually